Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK-US GCP Collaboration Going Strong But Mutual Recognition Not Feasible

Health Canada Has Also Joined The Partnership

Executive Summary

While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.

You may also be interested in...



EU, US Finally Agree On Mutual Recognition Of GMP Inspections

Reliance on each other’s good manufacturing practice reports should allow EU and US regulators to better focus their limited inspection resources on drug manufacturers in other countries around the world.

US/EU joint trial inspections pilot thrives, may extend to other agencies

Clinical trial inspectors from the US and the European Union are making strides in a joint inspections pilot programme they embarked on last year to identify how good clinical practice inspections can be conducted more effectively1,2.

UK To Reveal How Sponsors Are Performing On Trial Transparency Expectations

The UK is tightening its approach to enforcing best practices in clinical trial transparency.

Topics

UsernamePublicRestriction

Register

PS141756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel